Collaborate Disseminate
Biotech firm Moderna has commenced human trials testing an mRNA influenza vaccine targeting four separate viral strains. Building on its profoundly successful mRNA COVID-19 vaccine, the company is ultimately planning to develop a single vaccine against… Continue reading The mRNA flu vaccine race heats up with two human trials commencing
A new study from Stanford University researchers has found previous recent exposure to common coronaviruses could help explain why some people infected with SARS-CoV-2 only suffer mild symptoms. The research showed specific immune cells from patients w… Continue reading Mild COVID-19 symptoms linked to prior exposure to the common cold
Late in 2020, two experimental mRNA COVID-19 vaccines delivered stunningly positive final phase human trial results. With efficacy higher than 90 percent, the Pfizer and Moderna vaccines introduced the world to an entirely new kind of biotechnology, an… Continue reading Once-promising mRNA COVID-19 vaccine disappoints with final trial data
New research is showing that although some vaccinated people are still contracting COVID-19, they generally experience milder disease for a shorter period of time with a low viral load. The study, published in the New England Journal of Medicine, offer… Continue reading COVID-19 infections are rare and mild after vaccination
Japanese researchers have developed a new type of cholera vaccine by genetically modifying rice to carry a non-toxic cholera antigen. The vaccine needs no refrigeration with the rice simply ground into a powder, mixed with water and consumed.Continue R… Continue reading Genetically modified rice used for edible, easily stored cholera vaccine
Eighteen months after the first officially reported SARS-CoV-2 cases appeared in Wuhan we can now begin to investigate questions that were impossible to answer early on in the pandemic, such as what kind of immunity is generated from a natural infectio… Continue reading Why COVID-19 vaccines can provide stronger immunity than natural infection
UK health authorities are reporting 90 percent of new coronavirus infections are due to the Delta variant. In the US the Centers for Disease Control and Prevention warn the variant will likely become predominant in the coming months. What is the Delta … Continue reading What is the Delta variant and how is it altering the course of the pandemic?
The pursuit of a vaccine for malaria has always been an important one, with more than 400,000 people dying from the disease every year. But with the parasite behind it becoming resistant to drugs and the mosquitoes that spread it becoming more resistan… Continue reading “Mosquito smoothies” streamline production of promising malaria vaccine
Biotechnology company Novavax has announced the long-awaited results from its large Phase 3 COVID-19 vaccine trial, revealing over 90 percent protection from symptomatic infection and 100 percent protection from moderate to severe disease. The vaccine … Continue reading Novavax COVID-19 vaccine hits 90% efficacy in large US trial
Pathogens like bacteria and viruses are extremely good at evolving in response to drugs, which can render vaccines ineffective. But now, researchers at ETH Zurich have found a way to weaponize that ability against them, forcing the bugs down harmless e… Continue reading Experimental vaccine forces bacteria down an evolutionary dead end